Aim: To evaluate safety and motor function after treatment with allogeneic umbilical cord blood (AlloCB) or umbilical cord tissue‐derived mesenchymal stromal cells (hCT‐MSC) in children with cerebral palsy (CP).Method: Ninety‐one children (52 males, 39 females; median age 3 years 7 months [range 2–5 years]) with CP due to hypoxic–ischemic encephalopathy, stroke, or periventricular leukomalacia were randomized to three arms: (1) the AlloCB group received 10 × 107 AlloCB total nucleated cells (TNC) per kilogram at baseline (n = 31); (2) the hCT‐MSC group received 2 × 106 hCT‐MSC at baseline, 3 months, and 6 months (n = 28); (3) the natural history control group received 10 × 107 AlloCB TNC per kilogram at 12 months (n = 31). Motor function was assessed with the Gross Motor Function Measure‐66 (GMFM‐66) and Peabody Developmental Motor Scale, Second Edition.Results: Infusions (n = 143) were well tolerated, with eight infusion reactions (three in the AlloCB group, five in hCT‐MSC) and no other safety concerns. At 12 months, the mean differences (95% confidence intervals [CI]) between actual and expected changes in GMFM‐66 score were AlloCB 5.8 points (3.4–8.2), hCT‐MSC 4.3 (2.2–6.4), and natural history 3.1 (1.4–5.0). In exploratory, post hoc analysis, the mean GMFM‐66 score (95% CI) of the hCT‐MSC group was 1.4 points higher than natural history (−1.1 to 4.0; p = 0.27), and the AlloCB group was 3.3 points higher than natural history (0.59–5.93; p = 0.02) after adjustment for baseline Gross Motor Function Classification System level, GMFM‐66 score, and etiology.Interpretation: High‐dose AlloCB is a potential cell therapy for CP and should be further tested in a randomized, blinded, placebo‐controlled trial.What this paper adds: Unrelated donor allogeneic umbilical cord blood (AlloCB) and human umbilical cord tissue‐derived mesenchymal stromal cell infusion is safe in young children with cerebral palsy. Significant changes in motor function were not observed 6 months after treatment. One year later, treatment with AlloCB was associated with greater increases in Gross Motor Function Measure‐66 scores.
27 April 2020 in American Journal of Medical Genetics Part A
DROSHA encodes a ribonuclease that is a subunit of the Microprocessor complex and is involved in the first step of microRNA (miRNA) biogenesis. To date, DROSHA has not yet been associated with a Mendelian disease. Here, we describe two individuals with profound intellectual disability, epilepsy, white matter atrophy, microcephaly and dysmorphic features, who carry damaging de novo heterozygous variants in DROSHA. DROSHA is constrained for missense variants and moderately intolerant to loss-of-function (o/e = 0.24). The loss of the fruit fly ortholog drosha causes developmental arrest and death in third instar larvae, a severe reduction in brain size and loss of imaginal discs in the larva. Loss of drosha in eye clones causes small and rough eyes in adult flies. One of the identified DROSHA variants (p.Asp1219Gly) behaves as a strong loss-of-function allele in flies, while another variant (p.Arg1342Trp) is less damaging in our assays. In worms, a knock-in that mimics the p.Asp1219Gly variant at a worm equivalent residue causes loss of miRNA expression and heterochronicity, a phenotype characteristic of the loss of miRNA. Together, our data show that the DROSHA variants found in the individuals presented here are damaging based on functional studies in model organisms and likely underlie the severe phenotype involving the nervous system.
7 February 2020 in Developmental Medicine & Child Neurology